Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 93.68 CHF 2.32% Market Closed
Market Cap: 189.7B CHF
Have any thoughts about
Novartis AG?
Write Note

Operating Margin
Novartis AG

30.6%
Current
26%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
30.6%
=
Operating Profit
15.3B
/
Revenue
49.9B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CH
Novartis AG
SIX:NOVN
183.3B CHF
31%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
710.5B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
373.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
CH
Roche Holding AG
SIX:ROG
202.7B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP
21%
IE
Endo International PLC
LSE:0Y5F
146B USD
11%
US
Pfizer Inc
NYSE:PFE
145.4B USD
22%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
Country US
Market Cap 145.4B USD
Operating Margin
22%
No Stocks Found

Novartis AG
Glance View

Market Cap
183.3B CHF
Industry
Pharmaceuticals

Novartis AG, a global healthcare leader based in Switzerland, stands as a beacon of innovation in the pharmaceutical industry. With a rich history dating back to over a century, the company has evolved by focusing on developing innovative medicines and therapies that address serious health challenges across various therapeutic areas, including oncology, cardiovascular, neuroscience, and immunology. Novartis is particularly known for its commitment to research and development, consistently investing a significant portion of its revenue into discovering groundbreaking treatments. This strategy has yielded a robust portfolio of patented drugs, including blockbuster therapies that have transformed patient care and established Novartis as a dominant player in the market. For investors, Novartis presents a compelling opportunity nurtured by its strong financial performance, sustainable growth trajectory, and strategic focus on leveraging cutting-edge technology in drug discovery. The company enjoys a diversified revenue stream from both patented medicines and generics, thanks to its subsidiary Sandoz. Additionally, Novartis is actively engaging in transformative initiatives, such as adopting digital health solutions and pursuing gene therapies, positioning itself well for future growth in an increasingly competitive landscape. With a solid dividend history and a commitment to return value to shareholders, Novartis embodies the principles of sound investment, making it an appealing choice for those looking to invest in the burgeoning healthcare sector.

NOVN Intrinsic Value
90.85 CHF
Overvaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
30.6%
=
Operating Profit
15.3B
/
Revenue
49.9B
What is the Operating Margin of Novartis AG?

Based on Novartis AG's most recent financial statements, the company has Operating Margin of 30.6%.